m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03255)
Name
TGX-221
Synonyms
TGX 221
    Click to Show/Hide
Status
Investigative
Structure
Formula
C21H24N4O2
InChI
1S/C21H24N4O2/c1-15-12-18(16(2)22-17-6-4-3-5-7-17)21-23-19(13-20(26)25(21)14-15)24-8-10-27-11-9-24/h3-7,12-14,16,22H,8-11H2,1-2H3
InChIKey
CPRAGQJXBLMUEL-UHFFFAOYSA-N
PubChem CID
9907093
TTD Drug ID
D06DNH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
PI3-kinase beta (PIK3CB)
Methyltransferase-like 13 (METTL13)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
References
Ref 1 N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020 Dec;69(12):2180-2192. doi: 10.1136/gutjnl-2019-320179. Epub 2020 Apr 20.
Ref 2 Inactivation of PI(3)K p110Delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.